Beneficial effects of metformin on cancer risk and mortality have been proved by epidemiological and clinical studies, thus attracting research interest in elucidating the underlying mechanisms. Recently, tumour-associated macrophages (TAMs) appeared to be implicated in metformin-induced antitumour activities. However, how metformin inhibits TAMs-induced tumour progression remains ill-defined. Here, we report that metformin-induced antitumour and anti-angiogenic activities were not or only partially contributed by its direct inhibition of functions of tumour and endothelial cells. By skewing TAM polarization from M2-to M1-like phenotype, metformin inhibited both tumour growth and angiogenesis. Depletion of TAMs by clodronate liposomes eliminated M2-TAMs-induced angiogenic promotion, while also abrogating M1-TAMs-mediated anti-angiogenesis, thus promoting angiogenesis in tumours from metformin treatment mice. Further in vitro experiments using TAMs-conditioned medium and a coculture system were performed, which demonstrated an inhibitory effect of metformin on endothelial sprouting and tumour cell proliferation promoted by M2-polarized RAW264.7 macrophages. Based on these results, metformin-induced inhibition of tumour growth and angiogenesis is greatly contributed by skewing of TAMs polarization in microenvironment, thus offering therapeutic opportunities for metformin in cancer treatment.
| INTRODUCTION
Compelling evidences that the antidiabetic metformin reduces cancer risk and cancer-related mortality have increasingly attracted the attention of researchers. [1] [2] [3] In the last decade, researchers are performing clinical trials to evaluate the benefits of metformin for numerous early-stage and late-stage malignant tumours (https://clini caltrials.gov/). Recently, a large number of pre-clinical studies have been or are being carried out to elucidate the mechanisms underlying metformin's beneficial effects. [4] [5] [6] [7] As is reported, metformin exerted significant direct effects on inhibition of tumour cell functions in vitro, usually at concentrations equal or higher than 2 mmol/L. 8, 9 Besides, high concentrations of metformin have been proven to suppress endothelial proliferation, migration, and angiogenesis in vitro, 10 which is implicated in its antiangiogenic activity. 11 According to results of pharmacokinetic studies, this concentration is at least 50-fold excess over the plasma concentration of patients or experimental animals. 12, 13 Thus, these results based on high concentrations may be not enough to explain the beneficial actions of metformin in cancers.
Recently, metformin's antitumour and anti-angiogenic activities have been demonstrated to be associated with tumour-associated macrophages (TAMs), 14 a major component in microenvironment. 15 TAMs in tumours always differentiate into anti-inflammatory M2-like phenotype in hypoxic microenvironment, 16, 17 thus secreting cytokines to promote tumour progression and angiogenesis. 17, 18 However, how metformin affects the differentiation of TAMs into distinct phenotypes and the underlying mechanism remain poorly understood.
Given that skewing of TAM polarization is able to inhibit tumour progression, 19 we investigated the mechanism mediating the antitumour and anti-angiogenic effects of metformin, with focus on its previously documented immune modulatory effects.
| MATERIALS AND METHODS

| Cells and reagents
4T1 (murine breast cancer), CT-26 (murine colorectal cancer), Renca (murine renal cancer) and human umbilical endothelial cell (HUVEC) lines were obtained from American Type Culture Collection (ATCC).
Murine macrophage cell line RAW264.7 was kindly provided by the Key Laboratory of Cardiovascular Disease of Shaanxi Province.
Before performing cellular experiments, all cells were confirmed to be mycoplasma free (using Mycoplasma Test Kit). Cells were cultured in the Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) in an atmosphere of 5% CO 2 -95% air.
Clodronate (CLO) and control liposomes were purchased from LIPOSOMA (Amsterdam, Netherlands). Recombinant interleukin (IL)-13 was obtained from R&D SYSTEMs (Minnesota, USA). Propidium iodide (PI) was purchased from Sigma-Aldrich (Missouri, USA). 
| Flow cytometry
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| Macrophage-conditioned medium
Briefly, 1 9 10 6 RAW 264.7 macrophages were seeded into 6-well plates and pre-treated with metformin (1 mmol/L), IL-13 (15 ng/mL) or the combination treatment. Forty-eight hours later, supernatants were collected, centrifuged to remove cell debris and stored in the fridge (À80°C). Subsequently, macrophages were collected with a cell scraper, and the total cell number was counted for each well.
After that, loading of macrophage-conditioned medium was appropriately corrected according to the difference of macrophage number between wells (Because cell number would affect the total amount of cytokines secreted into the supernatant).
| Cellular viability and migration assay
For assessing cellular viability, cells were seeded into 24-well plates and subsequently cultured with metformin or conditioned medium of macrophages for 48 hours. After that, cellular viability was assessed using CCK-8 (Cell counting kit-8) assay kit (Dojindo, Japan) as previously described. 20 For observation of endothelial migration in vitro, 2 9 10 6
HUVECs were seeded and cultured in 6-well plates until confluence.
After that, well plates were vertically scratched using the tip of a 200-lL pipette. After gently washing, 3 mL of prepared macrophage-conditioned medium was added into duplicate per variant.
Twenty-four hours later, scratched crosses were photographed using a microscope at 1009 magnification.
| Coculture vascular sprouting assay
To observe the interaction between macrophage and ECs, a transwell insert system (with 0.4 lm pore) was employed. 
| Tube formation assay
In vitro endothelial tube formation assay was performed as described. 20 Briefly, wells of a 96-well plate were pre-coated with 10 lL Matrigel (at 37°C for 30 minutes for polymerization). Then, 2 9 10 4 HUVECs were seeded into these wells, and capillary-like network was recorded and analysed 24 hours later. For deletion of macrophages in vivo, tumour-bearing mice were intraperitoneally injected with 100 mg/kg of the clodronate liposome. 19 After that, 50 mg/kg of clodronate liposome was injected every fourth day to prevent repopulation of macrophages. CD68 + macrophages in both tumours and murine rectums were detected by IHC staining and counted to assess the efficiency of macrophage depletion.
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| Immunohistochemistry (IHC) and immunofluorescence (IF)
Mouse tissues were extracted, fixed, sectioned and immunostained as previously described. 20 Briefly, for IF staining, 4% paraformaldehyde (PFA)-fixed tissues were cut into 6 lm (for 2D confocal microscopy) or 40-50 lm (for 3D confocal microscopy). After blocking with BSA (bovine serum albumin, 5%), sections were permeabilized with 0.2% Triton X-100 (15 minutes), washed and stained with anti-CD31 More details about antibodies can be found in the Table S1 .
| Real-time qRT-PCR
To detect the change of mRNA levels of VEGF, FGF-2 and PlGF, a standardized real-time quantitative PCR was performed according to the manufacturer's instructions (Takara). Sequences of primers used for PCR can be found in the Table Table S1 .
| Statistical analysis
All measurement data were represented as mean AE SEM (if normally distributed) or median with interquartile range (if not normally distributed). For two-group comparison, student t test was used; for multiple-group (>2) comparison, Statistical significance of the difference was defined using one-way ANOVA (Prism5, San Diego, CA).
P < .05 is considered significant; P > .05 indicates not significant.
| RESULTS
| Systematic metformin administration reduces tumour growth
To evaluate the effects of metformin on tumour progression, we nutrients supplied by the newly formed vessels, 22 we explored whether metformin had inhibitory effects on tumour angiogenesis.
| Metformin inhibits tumour angiogenesis and normalized the morphology of vasculature
Cancers are characterized by a morphologically abnormal vasculature that is closely associated with the excessive angiogenesis. 
| Metformin-induced anti-angiogenesis is contributed by reduced VEGF expression
Because of the critical role of VEGF in tumour angiogenesis, we next measured the VEGF expression level in tumours by immunohistochemistry. VEGF was found to be highly expressed in tumours from untreated mice (control; Figure 2D ), which at least partially explains the excessive angiogenesis in 4T1 tumours. Metformin at a dose of 300 mg/kg day, but not 100 mg/kg day, significantly reduced expression levels of both VEGF and FGF-2 in tumours ( Figure 2D -G), indicating the involvement of VEGF and FGF-2 signalling in metformin-induced anti-angiogenesis.
| Metformin causes only a slight inhibition of EC functions
Previously published articles had demonstrated the direct inhibitory effects of metformin on EC functions. 10, 25 As direct targeting is capable of inhibiting tumour angiogenesis, we thus explored if metformin mediates anti-angiogenesis via an EC-dependent mechanism.
Under consideration of the higher accumulation of metformin in tissues than plasma, 12 we set concentrations ranging from 0.1 lmol/L to 1 mmol/L for further in vitro experiments, 14 which are more related to the clinically-applicated concentration range.
In vitro EC wound-healing assay showed that EC migration was not apparently affected by metformin even at 1 mmol/L concentration ( Figure 3A) . We next performed EC tube formation assay and investigated the direct effects of metformin on in vitro EC prolifera- 
| Metformin-induced anti-angiogenesis does not depend upon an EC-autonomous mechanism
We next examined the effects of metformin on endothelial cell cycle, and CT-26 cells ( Figure 4F ). We also investigated the effects of Figure 4C,D) . Thus, the discrepancy between metformin's antitumour and anti-angiogenic effects implies the existence of a cell non-autonomous mechanism in vivo.
| Metformin skews TAM polarization from
M2-to M1-phenotype
We next focused on TAMs, as they greatly contribute to tumour progression and new blood vessel formation. 
| Chemical TAM depletion abrogates the antiangiogenic effects of metformin
To investigate if metformin-induced anti-angiogenesis is contributed by skewing TAM polarization, we chemically depleted macrophages in tumour-bearing mice using CLO liposomes. To assess the depletion efficacy, tissue sections were immunostained with a CD68 antibody. As shown in Figure 6A ,B, CD68 + macrophages were reduced by 84% and Quantitative data are indicated as mean AE SEM. *P < .05; **P < .01; ***P < .001; "ns" indicates no statistically significant difference (P > .05)
| Metformin suppresses tumour proliferation and angiogenesis promoted by M2-like macrophages
We next analysed the impact of metformin on M2-like macrophageinduced promotion of tumour proliferation and angiogenesis in vitro.
Macrophages treated with IL-13 assume a M2-like phenotype.
14 When stimulated with IL-13, RAW264.7 macrophages were differentiated into M2-like rather than M1-like macrophages, as evidenced by intensely increased mRNA expression of Arg-1 (Figure 7A) , a M2 marker. In the presence of IL-13, metformin significantly decreased the expression level of Arg-1, while having no effect on expression of iNOS, a marker for M1, indicating that metformin is potential of inhibiting cytokine-induced M2 polarization of macrophages.
To get a deep understanding of metformin-induced anti-angiogenesis by targeting TAMs-ECs interaction, macrophages were F and G, Immunostaining for VEGF, revealing similar reduction in VEGF in metformin-treated 4T1 tumours from mice receiving CLO or not. G, Quantification of VEGF IHC score (addition of intensity score and positive signal area) of 4T1 tumours (n = 8). Quantitative data are indicated as mean AE SD *P < .05; **P < .01; ***P < .001 versus control vehicle. "ns" indicates no statistically significant difference (P > .05) cocultured with ECs using a Transwell Insert System ( Figure 7C ).
When cocultured with M2-polarized macrophages, ECs generated more and longer vascular sprouts than those not cocultured (Figure 7D,E) . In the absence of IL-13, metformin pre-treatment exhibited a significant inhibition of ECs-mediated vascular sprouting, suggesting that metformin is potential of suppressing M2-like macrophage-promoted endothelial angiogenesis. phages. 33 Macrophages that infiltrate tumours, also called TAMs, are the major component of microenvironment. 16 Most importantly, Macrophages were pre-treated with PBS (Con), 15 ng/mL IL-13 or in combination with 1 mmol/L metformin (Met) for 48 h (n = 6). Quantitative data are indicated as mean AE SEM. *P < .05; **P < .01; ***P < .001. "ns" indicates no statistically significant difference (P > .05)
targeting TAMs by skewing the polarization state had been demonstrated to be more effective than direct inhibition of cellular functions. 34 Based on these evidences, targeting TAMs has been widely accepted as one of the most promising therapeutic strategies for treating cancers. 15 15 Together with our results, it could be boldly deduced that, in addition to increasing T effector cell infiltration, metformin's antitumour effect also greatly depends on the skewing of TAMs polarization.
This speculation should be validated in the further investigation.
Metformin is best known as an AMPK activator, 37 but if AMPK activation is involved in metformin-induced effects on TAM polarization remains unclear. It was reported that AMPK signalling was closely involved in inflammatory cytokine-mediated polarization of macrophages. 38 Similarly, AICAR, an AMPK-specific activator, was found to significantly inhibit cytokine-induced M2-polarization of macrophages in vitro. 14 Despite these evidences, this mechanism has not yet been definitely elucidated in models of in vivo experiments.
At least, attentions should be focused on in situ observations of AMPK activation status in TAMs. Besides, in the previously published articles, 39 metformin had been shown to ameliorate hypoxic tumour microenvironment by elevating tumour blood perfusion. It is well known that hypoxia plays a crucial role in regulating polarization of TAMs in tumour microenvironment. 40 Although this mechanism was not investigated in this report, skewing of TAMs polarization might have been due to metformin-induced amelioration of hypoxic tumour microenvironment.
In the current paper, metformin inhibited tumour growth and angiogenesis by an indirect mechanism, which is different from the previously published articles that focused on metformin's direct effects on cellular functions. 7, 41, 42 High concentrations (equal or higher than 2 mmol/L) of metformin always exhibited significant inhibitory effects on tumour cell migration, proliferation and invasion, whereas low concentrations (<2 mmol/L) of metformin exhibited only a slight inhibitory effect. 7 Our in vitro results are consistent with these reported data basing on low concentrations of metformin. 29 Plasma concentrations of metformin are estimated to be consistently <0.2 mmol/L in diabetic patients and experimental animals. 12, 13, 43 Although tissue accumulation of metformin would result in a higher concentration in tissue than in plasma, tissue concentration of metformin was found to be <1 mmol/L. 43 Therefore, low concentrations of metformin may be more appropriate for exploring its antitumour activities in vitro.
The findings presented here from mechanistic experiments have implications for application of metformin as a clinical treatment for cancers. As metformin is a clinically approved drug, its property to induce inhibition of tumour growth and angiogenesis will make this agent more attractive for treatment of malignant tumours. Further efforts should be made to offer pathological evidences and validate the association between ameliorated hypoxic microenvironment and skewing of macrophage polarization.
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